Displaying 96 (all) recruiting clinical trials.
-
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
This study is about patients who have recently been diagnosed with early-stage classical Hodgkin lymphoma (cHL). The researchers want to compare two treatment approaches: one ...
-
A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
This study is to see if a new medicine called AK112 can help patients with advanced non-squamous non-small cell lung cancer (NSCLC) that didn't ...
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
The purpose of this study is to measure clinical efficacy of oral brepocitinib compared with placebo in participants with dermatomyositis. -
A 52-week Double-blind Placebo-controlled Randomized Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid
The purpose of this study is to determine the effects of seladelpar on normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC ... -
PRESERVE Heart Study
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS ... -
A Phase 3 Multi-Center Randomized Double-Blind Trial to Evaluate The Efficacy and Safety of Aficamten Compared To Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
The purpose of this research study is to compare the effects of aficamten and placebo on health status and exercise capacity in participants with non-obstructive ...